YH015 is a fully human anti-CD40 IgG1 antagonistic monoclonal antibody. YH015 was generated by our fully human antibody RenMice platform. It was screened out by our unique in vivo strategy and it has good in vivo and in vitro inhibitory activity and physicochemical properties.
Meanwhile, the mutation modification of the Fc of the antibody reduced the ADCC effect, prolonged the half-life of the drug, reduced the frequency of dosing, and had better clinical application value.
CD40 inhibitors have the potential to be developed into drugs for autoimmune diseases and organ transplantation. YH015 is currently at the CMC stage.